Literature DB >> 2790700

The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer.

H B Muss1, T E Kute, L D Case, L R Smith, C Booher, R Long, L Kammire, B Gregory, J K Brockschmidt.   

Abstract

Flow cytometry (FC) analysis including DNA index (ploidy status) and cell kinetics (%S and %S + G2/M) was done on frozen tissue of the primary lesions of 101 women with node negative (N-) breast cancer who were studied prospectively. Currently, 19% (19/101) of the patients have recurred. No significant relations have been found between recurrence or survival and age, estrogen/progesterone receptor status, tumor size, and tumor type. The DNA index (ploidy) was not related to any clinical variable, time to recurrence, or survival. Aneuploid tumors did, however, have significantly higher %S phase activity. Patients with %S activity less than or equal to the median value were significantly different from those patients with %S above the median. They were older and had a higher frequency of ER/PR positive and well- or moderately differentiated tumors. Patients with %S + G2/M greater than the median value showed shorter time to recurrence (P = .055) and shorter survival (P = .006), whereas %S alone was significantly associated only with survival. Multivariate analysis showed that neither DNA index nor cell kinetics was significantly associated with time to relapse. DNA index was not significantly associated with survival; %S was of borderline significance whereas %S + %G2/M was a significant independent predictor of survival. Although FC data may provide independent information related to survival in N-women, additional research in a larger number of patients is needed to define its precise role in patient management.

Entities:  

Mesh:

Year:  1989        PMID: 2790700     DOI: 10.1002/1097-0142(19891101)64:9<1894::aid-cncr2820640923>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  DNA ploidy, S-phase, and Ki-67 antigen expression in the evaluation of cell content of pleural effusions.

Authors:  J Sikora; G Dworacki; J Zeromski
Journal:  Lung       Date:  1996       Impact factor: 2.584

2.  Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.

Authors:  A E Pinto; S André; J Soares
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  Flow cytometric DNA hypertetraploidy is associated with unfavourable prognostic features in breast cancer.

Authors:  A E Pinto; S André; M Nogueira; E Mendonça; J Soares
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

4.  Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry.

Authors:  E Bergers; P J van Diest; J P Baak
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

Review 5.  Endocrine therapy for advanced breast cancer: a review.

Authors:  H B Muss
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

6.  DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.

Authors:  C R Wenger; S Beardslee; M A Owens; G Pounds; T Oldaker; P Vendely; M R Pandian; D Harrington; G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

Review 7.  DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.

Authors:  D W Hedley; G M Clark; C J Cornelisse; D Killander; T Kute; D Merkel
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

8.  Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinomas--a 10 year survival study.

Authors:  S B Ewers; R Attewell; B Baldetorp; A Borg; M Fernö; E Långström; D Killander
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

9.  Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma.

Authors:  A Bonetti; M Zaninelli; S Rodella; A Molino; L Sperotto; Q Piubello; F Bonetti; R Nortilli; M Turazza; G L Cetto
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

10.  S-phase fraction identifies high-risk subgroups among DNA-diploid breast cancers.

Authors:  H Romero; J Schneider; J Burgos; J Bilbao; F J Rodriguez-Escudero
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.